Lixte Biotechnology Holdings, Inc. (LIXT) financial statements (2023 and earlier)

Company profile

Business Address 248 ROUTE 25A
EAST SETAUKET, NY 11733
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,8245,0692,5994,2731,30620025
Cash and cash equivalents4,8245,0692,5994,2731,30620025
Receivables  14    
Prepaid expense10967 9   
Contract with customer, asset 77  
Other undisclosed current assets16015595262233573
Total current assets:5,0935,2282,6724,3341,368433598
Noncurrent Assets
Prepaid expense   2   
Total noncurrent assets:   2   
TOTAL ASSETS:5,0935,2282,6724,3371,368433598
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:226190144195312160159
Interest and dividends payable      2
Other undisclosed accounts payable and accrued liabilities226190144195312160157
Deferred revenue 16 
Due to related parties33      
Other undisclosed current liabilities441094166159127
Total current liabilities:303217238211373219286
Noncurrent Liabilities
Total liabilities:303217238211373219286
Stockholders' equity
Stockholders' equity attributable to parent4,7905,0122,4344,126995215312
Preferred stock3,5003,5003,5003,5003,5003,5001,750
Common stock1177655
Additional paid in capital38,37131,86426,01625,26820,00517,41717,130
Accumulated deficit(37,082)(30,354)(27,089)(24,649)(22,515)(20,707)(18,572)
Total stockholders' equity:4,7905,0122,4344,126995215312
TOTAL LIABILITIES AND EQUITY:5,0935,2282,6724,3371,368433598

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues
(Revenue, Net)
      200
Cost of revenue
(Cost of Goods and Services Sold)
(3,024)    (25)(53)
Gross profit:(3,024)    (25)147
Operating expenses(6,720)(3,266)(2,490)(2,138)(1,810)(2,135)(2,846)
Other undisclosed operating income3,024    2553
Operating loss:(6,720)(3,266)(2,490)(2,138)(1,810)(2,135)(2,646)
Nonoperating income (expense)(1)5505100
Investment income, nonoperating15505100
Foreign currency transaction loss, before tax(1)      
Interest and debt expense(7)(4)     
Net loss:(6,728)(3,265)(2,440)(2,133)(1,808)(2,135)(2,646)
Other undisclosed net loss attributable to parent      (206)
Net loss attributable to parent:(6,728)(3,265)(2,440)(2,133)(1,808)(2,135)(2,852)
Other undisclosed net loss available to common stockholders, basic      (2)
Net loss available to common stockholders, diluted:(6,728)(3,265)(2,440)(2,133)(1,808)(2,135)(2,854)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(6,728)(3,265)(2,440)(2,133)(1,808)(2,135)(2,646)
Comprehensive loss, net of tax, attributable to parent:(6,728)(3,265)(2,440)(2,133)(1,808)(2,135)(2,646)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: